It is important to be clear about where the evidence comes from: GHK-Cu is used overwhelmingly topically in cosmetics , where most of its human data small studies of creams and serums for skin firmness, fine lines and wound repair actually lies [6]
While the company has always traded at a premium valuation given its product mix, right now its trading at a P/E of 61
Because it mimics two different hormones, it has the potential to help patients see more significant weight loss than they might see with semaglutide
Several senior pharmaceutical company executives have complained that the NHSs ability to push a hard bargain when it comes to paying for drugs risks stifling innovation and investment in the UKs life sciences industry
Lilly reported producing more than 1.6 times the salable incretin doses in the first half of 2025 compared to the same period in 2024, with plans for significant additional manufacturing expansion [39]
The influence of environmental factors on premature ovarian insufficiency and ovarian aging